158 related articles for article (PubMed ID: 37383222)
21. Targeting mTOR network in colorectal cancer therapy.
Wang XW; Zhang YJ
World J Gastroenterol; 2014 Apr; 20(15):4178-88. PubMed ID: 24764656
[TBL] [Abstract][Full Text] [Related]
22. Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.
Evangelisti C; Chiarini F; Paganelli F; Marmiroli S; Martelli AM
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118635. PubMed ID: 31884070
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer.
Piawah S; Venook AP
Cancer; 2019 Dec; 125(23):4139-4147. PubMed ID: 31433498
[TBL] [Abstract][Full Text] [Related]
24. Protein kinase d as a potential chemotherapeutic target for colorectal cancer.
Wei N; Chu E; Wipf P; Schmitz JC
Mol Cancer Ther; 2014 May; 13(5):1130-41. PubMed ID: 24634417
[TBL] [Abstract][Full Text] [Related]
25. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T
J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152
[TBL] [Abstract][Full Text] [Related]
26. Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer.
Zhang Y; Zhang Y; Geng L; Yi H; Huo W; Talmon G; Kim YC; Wang SM; Wang J
J Biol Chem; 2016 Aug; 291(33):17405-16. PubMed ID: 27330076
[TBL] [Abstract][Full Text] [Related]
27. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
[TBL] [Abstract][Full Text] [Related]
28. MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
Chuang J; Wang C; Guo Y; Valenzuela V; Wu J; Fakih M
Clin Colorectal Cancer; 2021 Mar; 20(1):72-78. PubMed ID: 33436306
[TBL] [Abstract][Full Text] [Related]
29. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
Matos I; Elez E; Capdevila J; Tabernero J
Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
[TBL] [Abstract][Full Text] [Related]
30. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.
Guinney J; Ferté C; Dry J; McEwen R; Manceau G; Kao KJ; Chang KM; Bendtsen C; Hudson K; Huang E; Dougherty B; Ducreux M; Soria JC; Friend S; Derry J; Laurent-Puig P
Clin Cancer Res; 2014 Jan; 20(1):265-272. PubMed ID: 24170544
[TBL] [Abstract][Full Text] [Related]
31. Emerging roles of Aurora-A kinase in cancer therapy resistance.
Zheng D; Li J; Yan H; Zhang G; Li W; Chu E; Wei N
Acta Pharm Sin B; 2023 Jul; 13(7):2826-2843. PubMed ID: 37521867
[TBL] [Abstract][Full Text] [Related]
32. PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
Mangiapane LR; Nicotra A; Turdo A; Gaggianesi M; Bianca P; Di Franco S; Sardina DS; Veschi V; Signore M; Beyes S; Fagnocchi L; Fiori ME; Bongiorno MR; Lo Iacono M; Pillitteri I; Ganduscio G; Gulotta G; Medema JP; Zippo A; Todaro M; De Maria R; Stassi G
Gut; 2022 Jan; 71(1):119-128. PubMed ID: 33436496
[TBL] [Abstract][Full Text] [Related]
33. Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance.
Yeoh Y; Low TY; Abu N; Lee PY
PeerJ; 2021; 9():e12338. PubMed ID: 34733591
[TBL] [Abstract][Full Text] [Related]
34. Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.
Saturno G; Valenti M; De Haven Brandon A; Thomas GV; Eccles S; Clarke PA; Workman P
Oncotarget; 2013 Aug; 4(8):1185-98. PubMed ID: 23852390
[TBL] [Abstract][Full Text] [Related]
35. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.
Tie J; Desai J
Target Oncol; 2015 Jun; 10(2):179-88. PubMed ID: 25119972
[TBL] [Abstract][Full Text] [Related]
36. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
Efferth T
Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
[TBL] [Abstract][Full Text] [Related]
37. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
38. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
[TBL] [Abstract][Full Text] [Related]
39. Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs.
Choi HY; Chang JE
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686423
[TBL] [Abstract][Full Text] [Related]
40. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]